Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 350-355

  Herzog, Thomas J ^a   Vermorken, Jan B ^b   Pujade Lauraine, Eric ^c   Provencher, Diane M ^d   Jagiello Gruszfeld, Agnieszka ^e   Kong, Beihua ^f   Boman, Karin ^g   Park, Youn Choi ^h   Parekh, Trilok ^h   Lebedinsky, Claudia ⁱ   Gómez, Javier ⁱ   Monk, Bradley J ^j  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c HÔTEL DIEU   (France)

^d NOTRE DAME HOSPITAL   (Canada)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f SHANDONG UNIVERSITY   (China)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

ⁱ PHARMAMAR S A   (Spain)

^j CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

CA 125; Platinum; Relapsed ovarian cancer; Rustin criteria; Trabectedin

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; PLATINUM; TRABECTEDIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 79960441482     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.005     Document Type: Article

References (31)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
2. B.A. Goff, L.S. Mandel, C.H. Melancon, and H.G. Muntz Frequency of symptoms of ovarian cancer in women presenting to primary care clinics JAMA 291 2004 2705 2712 (Pubitemid 38725419)
3. B.A. Goff, L.S. Mandel, C.W. Drescher, N. Urban, S. Gough, and K.M. Schurman Development of an ovarian cancer symptom index: possibilities for earlier detection Cancer 109 2007 221 227 (Pubitemid 46106236)
4. N. Colombo, T. Van Gorp, G. Parma, F. Amant, G. Gatta, and C. Sessa Ovarian cancer Crit Rev Oncol Hematol 60 2006 159 179 (Pubitemid 44636248)
5. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
6. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214 (Pubitemid 11167383)
7. K.M. Hasebroock, and N.J. Serkova Toxicity of MRI and CT contrast agents Expert Opin Drug Metab Toxicol 5 2009 403 416
8. C. Suzuki, M.R. Torkzad, H. Jacobsson, G. Aström, A. Sundin, and T. Hatschek Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria Acta Oncol 49 2010 509 514
9. N.J. Carter, and S.J. Keam Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer Drugs 70 2010 355 376
10. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2010 2157 2163
11. G.J. Rustin, M. Quinn, T. Thigpen, A. Du Bois, E. Pujade-Lauraine, and A. Jakobsen New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488 (Pubitemid 38443654)
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. G.J. Rustin, R.C.J. Bast, G.J. Kelloff, J.C. Barrett, S.K. Carter, and P.D. Nisen Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 2004 3919 3926 (Pubitemid 38697628)
14. G.J. Rustin, A.E. Nelstrop, P. McClean, M.F. Brady, W.P. McGuire, and W.J. Hoskins Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 14 1996 1545 1551 (Pubitemid 26134212)
15. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057 (Pubitemid 32976692)
16. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
17. M.K. Tuxen, G. Soletormos, G.J. Rustin, A.E. Nelstrop, and P. Dombernowsky Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer Scand J Clin Lab Invest 60 2000 713 721 (Pubitemid 32094666)
18. J. Cohen A coefficient of agreement for nominal scales Educ Psychol Meas 20 1960 37 46
19. A. Poveda, I. Vergote, S. Tjulandin, B. Kong, M. Roy, and S. Chan Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 2010 10.1093/annonc/mdq352
20. S.B. Kaye, N. Colombo, B.J. Monk, S. Tjulandin, B. Kong, and M. Roy Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 2010 10.1093/annonc/mdq353
21. B. Slangen, J. Rolski, P. Gathage, M.B. Sawyer, V. Trillet-Lenoir, and S. Pledge Correlation of CA-125 and RECIST in the management of platinum-sensitive relapsed ovarian cancer (ROC): results from OVA-301 phase-III randomized study Int J Gynecol Cancer 20 2010 00581
22. T.J. Herzog, J.B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, and J. Gomez Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone J Clin Oncol 27 2009 abstract 5550
23. G. Ferrandina, M. Ludovisi, G. Corrado, V. Carone, M. Petrillo, and G. Scambia Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer Gynecol Oncol 109 2008 187 193
24. F. Badulescu, A. Badulescu, M. Schenker, C.F. Popescu, and Z. Stoica The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma Rom J Morphol Embryol 46 2005 329 334
25. B. Gronlund, C. Hogdall, J. Hilden, S.A. Engelholm, E.V. Hogdall, and H.H. Hansen Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22 2004 4051 4058 (Pubitemid 41199651)
26. G.J. Rustin, M.E. van der Burg, C.L. Griffin, D. Guthrie, A. Lamont, and G.C. Jayson Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163
27. R.J. Morgan Jr., J. Speyer, J.H. Doroshow, K. Margolin, J. Raschko, and J. Sorich Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels Gynecol Oncol 58 1995 79 85
28. E.M. Davelaar, J.M. Bonfrer, R.A. Verstraeten, W.W. ten Bokkel Huinink, and P. Kenemans CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer 78 1996 118 127 (Pubitemid 26189911)
29. R.L. Coleman, A. Gordon, J. Barter, S. Sun, W. Rackoff, and T.J. Herzog Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients Oncologist 12 2007 72 78 (Pubitemid 46143504)
30. P. Sabbatini, D. Mooney, A. Iasonos, H. Thaler, C. Aghajanian, and M. Hensley Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy Int J Gynecol Cancer 17 2007 589 594 (Pubitemid 46743996)
31. G. Gossner, R.L. Coleman, D.G. Mutch, N.S. Horowitz, J.S. Rader, and R.K. Gibb CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan Gynecol Oncol 103 2006 212 218 (Pubitemid 44374691)